Oncology pipeline
Cancer drug discovery: from insight to candidate-ready programs in 9-12 months, de-risking the path to IND and beyond.

Indivumed: A global biopharma partner specializing in individualized cancer therapy and biologic sample analysis.
indivumed.comCrawled Oct 21, 2026
Cancer drug discovery: from insight to candidate-ready programs in 9-12 months, de-risking the path to IND and beyond.
The excellent data approach to cancer drug development.
Indivumed’s process identifies low-toxicity, high-efficacy cancer targets.
Patient-derived cell cultures result in models that closely represent tumor biology.
Transforming promising cancer drug candidates into life-changing medicines.
The company offers access to a comprehensive multi-omics cancer database.
The page highlights cancer research and insights published in academic journals.
An article in LaBiotech discusses the company’s data-driven approach to cancer treatment for solid tumors.
The company has a paper published at MDPI titled “Applied Molecular-Based Quality Control of Biobanked Samples for Multi-Omics Approach.”
Biotechnology has developed into a central driver of medical innovation in life science hotspot Northern Germany.
Indivumed presents its oncology pipeline at ASCO 2026 in Chicago, integrating patient, target, and modality data.
The page provides updates on company news, scientific publications, and media coverage.
Indivumed showcases its precision oncology approach, data insights, and target discovery platform at JPM Week 2026.
The company contributes to advancing precision cancer therapy.
The Indivumed Global Clinical Network collects biospecimens and patient data using standardized processes.
Indivumed focuses on advancing oncological diagnosis and treatment through scientific research to improve patient outcomes worldwide.
Onco AI-Med is a collaborative network of leading oncologists and cancer researchers.
Indivumed discovers novel targets for the development of precision cancer therapeutics.
Indivumed collaborates with teams to develop first-in-class cancer treatments.
The company aims to provide cancer patients with targeted drugs tailored to their specific diseases.
Indivumed uses the Indivumed Global Clinical Network to collect biospecimens and patient information through a standardized process.
Indivumed discovers novel targets for the development of precision cancer therapeutics.
Onco AI-Med is a collaborative network of leading oncologists and cancer researchers.
Indivumed invites inquiries about joining its clinical network.
Indivumed welcomes questions about joining its team.
The newsletter updates readers on upcoming Indivumed activities.
Indivumed discovers new targets for precision cancer therapeutics.
Indivumed prioritizes privacy and complies with data protection regulations.
The page outlines video surveillance policies at Indivumed premises under GDPR.
Indivumed GmbH Marketing & PR Falkenried 88, Bldg. D D-20251 Hamburg Germany
Disclaimer – legal notices concerning www.indivumed.com